GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Net Margin %

Cronos Group (Cronos Group) Net Margin % : -187.29% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Cronos Group Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cronos Group's Net Income for the three months ended in Dec. 2023 was $-44.79 Mil. Cronos Group's Revenue for the three months ended in Dec. 2023 was $23.92 Mil. Therefore, Cronos Group's net margin for the quarter that ended in Dec. 2023 was -187.29%.

The historical rank and industry rank for Cronos Group's Net Margin % or its related term are showing as below:

CRON' s Net Margin % Range Over the Past 10 Years
Min: -613.54   Med: -167.53   Max: 4911.66
Current: -84.1


CRON's Net Margin % is ranked worse than
83.55% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 3.76 vs CRON: -84.10

Cronos Group Net Margin % Historical Data

The historical data trend for Cronos Group's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group Net Margin % Chart

Cronos Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,911.60 -156.55 -613.54 -194.51 -84.78

Cronos Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -358.03 -95.16 -43.95 -6.63 -187.29

Competitive Comparison of Cronos Group's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cronos Group's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cronos Group's Net Margin % falls into.



Cronos Group Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cronos Group's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-73.963/87.241
=-84.78 %

Cronos Group's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-44.79/23.915
=-187.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cronos Group  (NAS:CRON) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Cronos Group Net Margin % Related Terms

Thank you for viewing the detailed overview of Cronos Group's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cronos Group (Cronos Group) Business Description

Traded in Other Exchanges
Address
111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Executives
Kamran Khan director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii officer: VP, Controller C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd. 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc. 10 percent owner 6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm officer: Chief Financial Officer 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik officer: General Manager (Israel) 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore officer: Chief Financial Officer C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022